Literature DB >> 23578369

Different flavors of X-chromosome inactivation in mammals.

Cathérine Dupont1, Joost Gribnau.   

Abstract

Dosage compensation of X-linked gene products between the sexes in therians has culminated in the inactivation of one of the two X chromosomes in female cells. Over the years, the mouse has been the preferred animal model to study this X-chromosome inactivation (XCI) process in placental mammals (eutherians). Similar to the imprinted inactivation of the paternally inherited X chromosome (Xp) in marsupials (methatherians), the Xp is inactivated during early mouse development. In this eutherian model, cell derivatives of the primitive endoderm (PE) and trophectoderm (TE) will continue to display this imprinted form of XCI. Cells developing from the mouse epiblast will reactivate the Xp, and subsequently initiate XCI of either the Xp or the maternally inherited Xm, in a random manner. Examination of XCI in other eutherians and in metatherians, however, indicates clear differences in the form and timing of XCI. This review highlights and discusses imprinted and random XCI from such a comparative viewpoint.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23578369     DOI: 10.1016/j.ceb.2013.03.001

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  29 in total

1.  Imprinted X chromosome inactivation offers up a double dose of epigenetics.

Authors:  Nora Engel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-17       Impact factor: 11.205

Review 2.  Evolution of vertebrate sex chromosomes and dosage compensation.

Authors:  Jennifer A Marshall Graves
Journal:  Nat Rev Genet       Date:  2015-11-30       Impact factor: 53.242

Review 3.  The evolution of X chromosome inactivation in mammals: the demise of Ohno's hypothesis?

Authors:  Eugénie Pessia; Jan Engelstädter; Gabriel A B Marais
Journal:  Cell Mol Life Sci       Date:  2013-10-31       Impact factor: 9.261

Review 4.  Mutant ATRX: uncovering a new therapeutic target for glioma.

Authors:  Santiago Haase; María Belén Garcia-Fabiani; Stephen Carney; David Altshuler; Felipe J Núñez; Flor M Méndez; Fernando Núñez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

Review 5.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

6.  ATRX directs binding of PRC2 to Xist RNA and Polycomb targets.

Authors:  Kavitha Sarma; Catherine Cifuentes-Rojas; Ayla Ergun; Amanda Del Rosario; Yesu Jeon; Forest White; Ruslan Sadreyev; Jeannie T Lee
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

Review 7.  Neuroimmune mechanisms of stress: sex differences, developmental plasticity, and implications for pharmacotherapy of stress-related disease.

Authors:  Terrence Deak; Matt Quinn; John A Cidlowski; Nicole C Victoria; Anne Z Murphy; John F Sheridan
Journal:  Stress       Date:  2015-07-15       Impact factor: 3.493

8.  Sex-biased gene expression and evolution of the x chromosome in nematodes.

Authors:  Sarah Elizabeth Albritton; Anna-Lena Kranz; Prashant Rao; Maxwell Kramer; Christoph Dieterich; Sevinç Ercan
Journal:  Genetics       Date:  2014-05-02       Impact factor: 4.562

9.  Genomic imprinting, disrupted placental expression, and speciation.

Authors:  Thomas D Brekke; Lindy A Henry; Jeffrey M Good
Journal:  Evolution       Date:  2016-10-28       Impact factor: 3.694

10.  The effects of 2,4-dinitrophenol and d-glucose concentration on the development, sex ratio, and interferon-tau (IFNT) production of bovine blastocysts.

Authors:  Mark P Green; Alexandra J Harvey; Lee D Spate; Koji Kimura; Jeremy G Thompson; R Michael Roberts
Journal:  Mol Reprod Dev       Date:  2015-10-21       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.